Phototherapy compositions and methods
AssigneeOMJ Ireland Limited
InventorsDennis Decola, Curtis Cole
Life of this patent
Estimating the term…
Abstract
Compositions containing a photoactivable agent and an agent that absorbs or blocks extraneous radiation during phototherapy are useful and used in methods to treat leukocyte mediated autoimmune diseases such as psoriasis, CTCL, and vertiligo.
Claims35
A composition for use in phototherapy comprising a photoactivable compound and an agent that absorbs or blocks extraneous radiation.
A pharmaceutical oil-in-water emulsion composition comprising:
- (i) from about 0.05% to 0.4% of a psoralen or psoralen derivatives;
- (ii) from about 4% to 15% of an agent that absorbs or blocks extraneous radiation;
- (iii) from above about 0 to about 80% of water;
- (iv) from about 10% to 40% of a non-volatile organic oil;
- (v) from about 1 to 5% of a thickener;
- and
- (vi) from about 0.5% to 2% of an emulsifer.
A pharmaceutical oil-in-water emulsion composition comprising:
- 58% water, 3% sorbitol;
- 3.0%, 0.2% methyl paraben, 0.3% propyl paraben, 0.3% Carbopol 934, 1% Brij 721, 12.4% Finsolv TN, 7.5% octyl methoxycinnamate, 15% Wickenol 155, 2.0% sodium Stearate C-1, and 0.1% 8-methoxypsoralen (8-MOP).
A pharmaceutical oleaginous composition comprising an UVB absorbing agent, a photoactivable compound, and a non-volatile organic oil.
A method to alleviate at least one symptom of psoriasis, vitiligo, cutaneous T-cell lymphoma, sleroma, chronic lymphocytic leukemia, atopic dermatitis, or adult T-cell leukemia comprising the step of a) contacting a therapeutical pharmaceutical oil-in-water emulsion composition containing a photoactivable compound and an agent that absorbs or blocks extraneous radiation to an affected area, and b) irradiating the affected area with radiation sufficient to activate said photoactivable compound.
A method of claim 32 wherein the psoralen is 8-methoxypsoralen and the UVB absorbing agent is selected from ethylhexyl p-dimethylaminobenzoate;
- 2-ethylhexyl salicylate;
- 2-ethylhexyl-4-methoxycinnamate;
- and 3,3,5-trimethyl-cyclohexyl salicylate;
- and the UVA absorbing agent is 4-(1,1-dimethylethyl)-4′-methoxydibenzoylmethane.
Dependencies are inferred from the claim text.